Actos and Biktarvy

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Pioglitazone may reduce the blood levels of bictegravir, which may make the medication less effective in some cases. Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe alternatives that do not interact, or you may need a dose adjustment or more frequent monitoring to safely use both medications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

MONITOR: Coadministration with inducers of CYP450 3A4, particularly those that can also induce uridine diphosphate glucuronosyltransferase (UGT) 1A1, may decrease the plasma concentrations of bictegravir. According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported. In healthy study subjects, administration of a single 75 mg dose of bictegravir during treatment with rifampin 600 mg once daily decreased mean bictegravir peak plasma concentration (Cmax) and systemic exposure (AUC) by 28% and 75%, respectively, compared to administration of bictegravir alone. When bictegravir 75 mg once daily was coadministered with rifabutin 300 mg once daily, mean bictegravir Cmax, AUC and trough plasma concentration (Cmin) decreased by 20%, 38% and 56%, respectively. These results are consistent with the fact that rifampin is a more potent inducer of CYP450 3A4 than rifabutin. Rifampin is also a known inducer of UGT1A1. The interaction has not been studied with other, less potent inducers than rifampin and rifabutin.

MANAGEMENT: The potential for diminished pharmacologic effects of bictegravir should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected.

Actos

Generic Name: pioglitazone

Brand name: Actos

Synonyms: n.a.

What is Actos?

Biktarvy

Generic Name: bictegravir / emtricitabine / tenofovir alafenamide

Brand name: Biktarvy

Synonyms: n.a.

What is Biktarvy?